Advances in Therapy

, Volume 29, Issue 7, pp 645–653 | Cite as

Comparison of Tacrolimus, Fluorometholone, and Saline in Mild-to-Moderate Contact Lens-Induced Papillary Conjunctivitis

  • Hongxing Diao
  • Zhihui She
  • Dan Cao
  • Zhichong Wang
  • Z. Lin
Original Research



The purpose of this study was to compare the efficacy of tacrolimus, fluorometholone, and saline in the treatment of mild to moderate contact lens-induced papillary conjunctivitis (CLPC).


This was a double-masked, randomized pilot study. A total of 18 soft contact lens users (n = 36 eyes) with mild to moderate papillary conjunctivitis were enrolled. Subjects were randomly assigned into three groups to receive tacrolimus 0.05%, fluorometholone 0.1%, or saline (sodium chloride 0.9%). Drugs were prescribed at the baseline visit (visit 1) and instilled twice daily for 4 weeks. Follow-up visits were taken at week 1 (visit 2), week 2 (visit 3), week 4 (visit 4, drug usage suspended at this visit), and week 6 (visit 5, 2 weeks after interrupting eye drops). Contact lens use was discontinued during the 6 weeks of the study, and variables assessed were symptoms and signs, tear film status, and intraocular pressures. Conjunctival impression cytology was performed at baseline and visit 5 to assess ocular surface status.


Mean roughness and redness scores decreased significantly from visit 1 to visit 5, but the variation tendency was comparable in all groups (P = 0.180 and 0.889, respectively). Subjective symptom parameters were improved in all CLPC patients at visit 5, and there was no remarkable difference in symptom reduction in three groups. The mean Schirmer value and mean break-up time (BUT) did not change significantly in the three groups during the study. Ocular surface findings by impression cytology improved significantly after three treatments. Intraocular pressure fluctuation from baseline to 6-week follow-up was not statistically significant in all subjects. No adverse treatment-related event was observed in any study group.


Tacrolimus 0.05% may be a safe and effective treatment for mild to moderate CLPC and is comparable with fluorometholone 0.1% in efficacy. Contact lens cessation accompanied with saline may also be effective in treating mild to moderate CLPC.


Contact lens-induced papillary conjunctivitis Fluorometholone Saline Tacrolimus 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Spring TF. Reaction to hydrophilic lenses. Med J Aust. 1974;1:449–450.PubMedGoogle Scholar
  2. 2.
    Grant T. Clinical aspects of planned replacement and disposable lenses. In: Kerr C, ed. The Contact Lens Yearbook 1991. Kent: Medical and Scientific Publishing; 1991:7–11.Google Scholar
  3. 3.
    Alemany A, Redal A. Giant papillary conjunctivitis in soft and rigid lens wear. Contactologica. 1991;13:14–20.Google Scholar
  4. 4.
    Donshik PC, Ehlers WH, Ballow M. Giant papillary conjunctivitis. Immunol Allergy Clin North Am. 2008;28:83–103, vi.PubMedCrossRefGoogle Scholar
  5. 5.
    Suchecki JK, Donshik P, Ehlers WH. Contact lens complications. Ophthalmol Clin North Am. 2003;16:471–484.PubMedCrossRefGoogle Scholar
  6. 6.
    Skotnitsky CC, Naduvilath TJ, Sweeney DF, Sankaridurg PR. Two presentations of contact lens-induced papillary conjunctivitis (CLPC) in hydrogel lens wear: local and general. Optom Vis Sci. 2006;83:27–36.PubMedCrossRefGoogle Scholar
  7. 7.
    Stapleton F, Stretton S, Sankaridurg PR, Chandoha H, Shovlin J. Hypersensitivity responses and contact lens wear. Cont Lens Anterior Eye. 2003;26:57–69.PubMedCrossRefGoogle Scholar
  8. 8.
    Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/ antihistaminic agent. J Ocul Pharmacol Ther. 1996;12:389–400.PubMedCrossRefGoogle Scholar
  9. 9.
    Khurana S, Sharma N, Agarwal T, et al. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis. Eye Contact Lens. 2010;36:210–214.PubMedCrossRefGoogle Scholar
  10. 10.
    Ilyas H, Slonim CB, Braswell GR, Favetta JR, Schulman M. Long-term safety of loteprednol etabonate 0.2% in the treatment of seasonal and perennial allergic conjunctivitis. Eye Contact Lens. 2004;30:10–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Fujishima H, Fukagawa K, Takano Y, et al. Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25:265–270.PubMedCrossRefGoogle Scholar
  12. 12.
    Costagliola C, Cati-Giovannelli B, Piccirillo A, Delfino M. Cataracts associated with long-term topical steroids. Br J Dermatol. 1989;120:472–473.PubMedCrossRefGoogle Scholar
  13. 13.
    Kymionis GD, Goldman D, Ide T, Yoo SH. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea. 2008;27:228–229.PubMedCrossRefGoogle Scholar
  14. 14.
    Yuan J, Zhai JJ, Chen JQ, Ye CT, Zhou SY. Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration. J Ocul Pharmacol Ther. 2009;25:345–350.PubMedCrossRefGoogle Scholar
  15. 15.
    Fei WL, Chen JQ, Yuan J, Quan DP, Zhou SY. Preliminary study of the effect of FK506 nanospheric-suspension eye drops on rejection of penetrating keratoplasty. J Ocul Pharmacol Ther. 2008;24:235–244.PubMedCrossRefGoogle Scholar
  16. 16.
    Ohashi Y, Ebihara N, Fujishima H, et al. A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2010;26:165–174.PubMedCrossRefGoogle Scholar
  17. 17.
    Zhai J, Gu J, Yuan J, Chen J. Tacrolimus in the treatment of ocular diseases. BioDrugs. 2011;25:89–103.PubMedCrossRefGoogle Scholar
  18. 18.
    Terry RL, Schnider CM, Holden BA, et al. CCLRU standards for success of daily and extended wear contact lenses. Optom Vis Sci. 1993;70:234–243.PubMedCrossRefGoogle Scholar
  19. 19.
    Nelson JD, Wright JC. Conjunctival goblet cell densities in ocular surface disease. Arch Ophthalmol. 1984;102:1049–1051.PubMedCrossRefGoogle Scholar
  20. 20.
    Brodsky M. Allergic conjunctivitis and contact lenses: experience with olopatadine hydrochloride 0.1% therapy. Acta Ophthalmol Scand Suppl. 2000:56–59.Google Scholar
  21. 21.
    Allansmith MR, Korb DR, Greiner JV. Giant papillary conjunctivitis induced by hard or soft contact lens wear: quantitative histology. Ophthalmology. 1978;85:766–778.PubMedGoogle Scholar
  22. 22.
    Remitz A, Virtanen HM, Reitamo S, Kari O. Tacrolimus ointment in atopic blepharoconjunctivitis does not seem to elevate intraocular pressure. Acta Ophthalmol. 2011;89:e295–e296.PubMedCrossRefGoogle Scholar
  23. 23.
    Furth S, Neu A, Colombani P, Plotnick L, Turner ME, Fivush B. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. Pediatr Nephrol. 1996;10:64–66.PubMedCrossRefGoogle Scholar
  24. 24.
    Bensignor E, Olivry T. Treatment of localized lesions of canine atopic dermatitis with tacrolimus ointment: a blinded randomized controlled trial. Vet Dermatol. 2005;16:52–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Kapoor KG, Mirza SN, Gonzales JA, Gibran SK. Visual loss associated with tacrolimus: case report and review of the literature. Cutan Ocul Toxicol. 2010;29:137–139.PubMedCrossRefGoogle Scholar
  26. 26.
    Moon JW, Shin KC, Lee HJ, Wee WR, Lee JH, Kim MK. The effect of contact lens wear on the ocular surface changes in keratoconus. Eye Contact Lens. 2006;32:96–101.PubMedCrossRefGoogle Scholar
  27. 27.
    Tomatir DK, Erda N, Gurlu VP. Effects of different contact lens materials and contact lens-wearing periods on conjunctival cytology in asymptomatic contact lens wearers. Eye Contact Lens. 2008;34:166–168.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2012

Authors and Affiliations

  • Hongxing Diao
    • 1
  • Zhihui She
    • 1
  • Dan Cao
    • 1
  • Zhichong Wang
    • 1
  • Z. Lin
    • 1
  1. 1.Zhongshan Ophthalmic CenterGuangzhouPeople’s Republic of China

Personalised recommendations